Efficacy and Safety of Clearing Heat and Detoxifying Injection in the Treatment of Influenza: A Randomized, Double‐Blinded, Placebo‐Controlled Trial
Authors:
Open Access
- 1 January 2014
- journal article
- research article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2014 (1) , 151235
Abstract
Objective. To evaluate the efficacy and safety of CHDI in the treatment of influenza infection. Method. A randomized double‐blind, double dummy trial was conducted. Influenza patients with a positive influenza A rapid test diagnosis were randomized to receive CHDI or oseltamivir. Primary outcome was assessed by the median fever alleviation time and clearance time, and secondary outcome was total scores of influenza symptoms. Results. One hundred thirty‐nine participants were screened and 34 had a RT‐PCR laboratory confirmation of influenza virus infection. Fever alleviation time was 2.5 and 5 hours in CHDI and oseltamivir, respectively, and fever clearance time was 32.5 and 49 hours. The HR of fever alleviation and clearance time shows no significant difference between two groups. Total scores of influenza symptoms descended significantly in both groups after treatment and descended more in CHDI than oseltamivir on day 2. Similar to total symptoms severity score, fever severity score descend more significantly in CHDI than oseltamivir on day 2, and there were no differences on other symptoms. Conclusions. CHDI have a similar effect to oseltamivir in reducing the duration of influenza illness. CHDI was well tolerated, with no serious adverse events noted during the study period.Keywords
Funding Information
- Jiangsu kangyuan pharmaceutical co. LTD
This publication has 24 references indexed in Scilit:
- Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trialBMJ, 2013
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in ChildrenNew England Journal of Medicine, 2000
- Efficacy and Safety of the Neuraminidase Inhibitor Zanamivirin the Treatment of Influenza A and B Virus InfectionsThe Journal of Infectious Diseases, 1999
- Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic AnalysesPharmacoEconomics, 1999
- Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus InfectionsNew England Journal of Medicine, 1997
- The Effectiveness of Vaccination against Influenza in Healthy, Working AdultsNew England Journal of Medicine, 1995
- Effect of influenza B virus infection on human performance.BMJ, 1993
- Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in FamiliesNew England Journal of Medicine, 1989
- Economic impact of influenzaThe American Journal of Medicine, 1987
- Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adultsAntimicrobial Agents and Chemotherapy, 1981